<DOC>
	<DOCNO>NCT01287260</DOCNO>
	<brief_summary>This clinical study evaluate superiority efficacy assess safety tolerability BAYA1040_Nifedipine 80 mg/day ( 40 mg twice daily ) compare BAYA1040_Nifedipine 40 mg/day ( 40 mg daily ) patient essential hypertension target blood pressure BAYA1040_Nifedipine 40 mg daily treatment .</brief_summary>
	<brief_title>High Dose BAYA1040_Nifedipine : Dose-comparative Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>20 year old Japanese male female Outpatient essential hypertension Patients whose sit diastolic blood pressure ( DBP ) 90 mmHg despite 4 week treatment antihypertensive drug Sitting diastolic blood pressure ( DBP ) 110 mmHg sit systolic blood pressure ( SBP ) 180 mmHg Patients secondary hypertension hypertensive emergency</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>BAYA1040_Nifedipine</keyword>
	<keyword>Nifedipine</keyword>
	<keyword>Essential hypertension</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase III</keyword>
	<keyword>13176</keyword>
</DOC>